Saratoga Research & Investment Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASML
ASML
|
+$38.3M |
| 2 |
Eli Lilly
LLY
|
+$25.9M |
| 3 |
JPMorgan US Quality Factor ETF
JQUA
|
+$7.6M |
| 4 |
Honeywell
HON
|
+$1.85M |
| 5 |
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
+$1.31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RTX Corp
RTX
|
+$40.1M |
| 2 |
Cisco
CSCO
|
+$26.8M |
| 3 |
Biogen
BIIB
|
+$25.2M |
| 4 |
Oracle
ORCL
|
+$23.4M |
| 5 |
Unilever
UL
|
+$22.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.72% |
| 2 | Communication Services | 15.66% |
| 3 | Consumer Staples | 14.21% |
| 4 | Healthcare | 13.52% |
| 5 | Industrials | 12.26% |
Similar funds
Saratoga Research & Investment Management's Q4 2024 Portfolio in Review
As of Q4 2024, Saratoga Research & Investment Management held 44 positions worth $1.98B, down 13% from $2.28B the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Saratoga Research & Investment Management withdrew a net $222M in Q4 2024, reducing 36 holdings. Its largest reduction was RTX Corp, cutting an estimated $40.1M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 22% a quarter earlier, followed by Communication Services and Consumer Staples.
Against the trend, Saratoga Research & Investment Management opened a new position in Eli Lilly worth $24.2M.
- Saratoga Research & Investment Management's largest Q4 2024 buy was Eli Lilly: 31,307 shares worth $24.2M.
- Saratoga Research & Investment Management added most to ASML in Q4 2024, an estimated $38.3M increase.
- Saratoga Research & Investment Management's biggest Q4 2024 reduction was RTX Corp, cutting an estimated $40.1M.
- Saratoga Research & Investment Management's ten largest holdings make up 60% of its $1.98B portfolio in Q4 2024.
- Saratoga Research & Investment Management opened 3 new positions and closed 0 in Q4 2024.
- Saratoga Research & Investment Management's portfolio value fell 13% quarter-over-quarter to $1.98B.
Based on Saratoga Research & Investment Management's 13F filing for Q4 2024, filed 12 Feb 2025.